Index reshuffle puts Agios Pharmaceuticals in the growth spotlight

Agios Pharmaceuticals (AGIO) has shifted index buckets, dropping from the Russell 2000 Value-Defensive and Defensive indices while being added to several Russell growth benchmarks on 27 June 2026.

This reclassification places Agios Pharmaceuticals alongside companies screened for growth characteristics across the Russell 2000 Growth, Russell 3000 Growth, Russell 3000E Growth, Russell 2500 Growth, and Russell Small Cap Comp Growth benchmarks.

The index reshuffle comes after a strong recent run in Agios Pharmaceuticals' share price, with a 30 day share price return of 32.84% and a year to date share price return of 38.26%. However, the 5 year total shareholder return of 35.41% highlights how long term holders have experienced a much bumpier journey.

If this growth reclassification has you looking beyond Agios Pharmaceuticals, it could be a good moment to scan the market for other high growth healthcare opportunities through our 40 healthcare AI stocks.

With Agios Pharmaceuticals now framed as a growth stock, a key question is whether the recent share price surge and shift into growth indices still leaves upside on the table or if the market is already baking in future gains.

Most Popular Narrative: 8.1% Undervalued

On the most followed narrative, Agios Pharmaceuticals screens as modestly undervalued, with a fair value of $40.88 against the last close of $37.58 and a steep discount to the long term cash flow estimate.

Upcoming potential FDA approval and commercial launch of PYRUKYND for thalassemia in the U.S. is set to significantly expand Agios' addressable market, driven by the high rate of disease diagnosis through newborn screening and well-defined patient populations, which should lift revenue growth in coming years.

Curious what supports that fair value for Agios Pharmaceuticals? The narrative leans on rapid revenue build, margin expansion, and a premium future earnings multiple. The exact hurdles and milestones behind those assumptions sit in the detailed projections.

Result: Fair Value of $40.88 (UNDERVALUED)

However, this Agios Pharmaceuticals narrative could be knocked off course if PYRUKYND faces safety setbacks or if ongoing high R&D spending keeps losses elevated for longer.

Another View on Agios Pharmaceuticals Valuation

The most followed narrative suggests Agios Pharmaceuticals is modestly undervalued, but the price to sales ratio of 33.8x paints a very different picture. That multiple sits well above the US Biotechs industry at 12x and peers at 3.1x, and even above the fair ratio of 0x, which points to meaningful valuation risk if expectations reset.

To see what the numbers say about this price, check the detailed valuation breakdown in our See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Uncertain whether the mixed signals around Agios Pharmaceuticals tilt more toward risk or reward? Act promptly, review the underlying assumptions, and weigh the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Agios Pharmaceuticals?

If Agios Pharmaceuticals has caught your attention, do not stop there. Broaden your watchlist now so you are not late to the next opportunity.

• Spot potential value early by scanning companies that look mispriced on quality and fundamentals through the 44 high quality undervalued stocks.
• Secure more dependable cash flow potential by focusing on companies offering robust income profiles with the 7 dividend fortresses.
• Reduce portfolio stress by focusing on resilient companies using the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.